Group 1 - Beam Therapeutics Inc. announced an underwritten offering of 16,151,686 shares of common stock at a price of $28.48 per share, along with pre-funded warrants for 1,404,988 shares at $28.47 each, expecting gross proceeds of approximately $500 million [1][2] - The offering is expected to close on or about March 11, 2025, subject to customary closing conditions [1] - J.P. Morgan, Jefferies, Cantor, Citigroup, and Wells Fargo Securities are acting as joint book-running managers for the offering [3] Group 2 - The net proceeds from the offering will be used for advancing Beam's platform technology, research and development activities, and pre-commercialization efforts for its base editing programs, including clinical trials for BEAM-101 and BEAM-302 [2] - Beam Therapeutics is focused on establishing a leading platform for precision genetic medicines, utilizing its proprietary base editing technology to enable precise genetic modifications [6]